# Cochlear

> Cochlear is a VC fund in Sydney backing Health Care and Medical. See 5 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Sydney, Australia
- Total investments: 5
- Last investment: Aug 2021
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/cochlear
- X (Twitter): https://twitter.com/CochlearGlobal
- Website: http://www.cochlear.com
- Facebook: https://www.facebook.com/cochlear

Cochlear is a VC fund in Sydney focused on Health Care and Medical. Cochlear help people hear and be heard. The company empowers people to connect with others and live a full life. They help transform the way people understand and treat hearing loss. They innovate and bring to market a range of implantable hearing solutions that deliver a lifetime of hearing outcomes.

## Contacts

5 contacts available for Cochlear. Shizune tracks 10 team members at Cochlear. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/cochlear?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 60% |
| Medical | 2 | 40% |
| Medical Device | 2 | 40% |
| Neuroscience | 1 | 20% |
| Biotechnology | 1 | 20% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 20% |
| Series C | 1 | 20% |
| Series D | 1 | 20% |
| Corporate Round | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 1 | 20% |
| Australia | 1 | 20% |
| United States | 1 | 20% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Benedikt Funke | System Project Manager | 0 | — |
| Brent Cubis | Chief Financial Officer | 0 | — |
| Brian Kaplan | SVP Clinical Strategy and Innovation | 0 | — |
| Dean Phizacklea | Senior Vice President of Global Marketing | 0 | — |
| Dig Howitt | CEO and President | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Seer | Seer is a medical technology company that specializes in the diagnosis and management of neurological conditions. Its technology consists of wearable devices, a cloud platform, and machine learning systems. The company is driven by a mission to empower people by delivering personalized deep clinical insights by utilizing the latest technology.Seer was founded in 2016 and is headquartered in Melbourne, Victoria. | $24.9M | Series A | Aug 27, 2021 |  |
| Nyxoah | Nyxoah is a health-technology company focused on the development and commercialization of innovative solutions and services to treat sleep disordered breathing conditions. Nyxoah's lead solution platform is based on the Genio® system, a validated, user-centered, next generation neurostimulation therapy for OSA, the world's most commonsleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke. | $27.2M | Corporate Round | Feb 12, 2020 |  |
| Earlens | Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss.The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. Thisrevolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum. | $87M | Series D | Oct 22, 2018 |  |
| Earlens | Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss.The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. Thisrevolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum. | $73M | Series C | Jun 05, 2017 |  |
| Earlens | Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss.The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. Thisrevolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum. | $34M | Series C | Jun 16, 2016 |  |

5 of 5 investments shown.

## Co-investors
- [Aisling Capital](https://shizune.co/investors/profile/aisling-capital) — VC Fund, 3 deals together
- [Lightstone Ventures](https://shizune.co/investors/profile/lightstone-ventures) — VC Fund, 3 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 3 deals together
- [Vertex Ventures](https://shizune.co/investors/profile/vertex-ventures) — VC Fund, 3 deals together
- [Vertex Ventures HC](https://shizune.co/investors/profile/vertex-ventures-hc) — VC Fund, 3 deals together
- [Medtronic](https://shizune.co/investors/profile/medtronic) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Cochlear invest in?

Cochlear invests primarily in Health Care, Medical and Medical Device startups, most often at Series A and Series C stage. Most of the 5 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Cochlear?

Public channels for Cochlear include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Cochlear?

The team at Cochlear includes Benedikt Funke (System Project Manager), Brent Cubis (Chief Financial Officer) and Brian Kaplan (SVP Clinical Strategy and Innovation), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co